ClinicalTrials.gg
CompletedNCT01552915Updated Jun 8, 2021Results posted

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

A Phase 4 interventional study of Lisdexamfetamine dimesylate and Methylphenidate Hydrochloride in Attention-deficit/Hyperactivity Disorder, sponsored by Shire. Completed at 79 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
2nd of 51
464 · median 48
Started
2012
with 2 others
Phase 4
23 of 51
none open now
Registered
33rd of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 2nd largest by enrollment, is one of 3 that started in 2012, is one of 23 in phase 4, and was the 33rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).

03

Conditions studied

  • Attention-deficit/Hyperactivity Disorder

Keywords

  • ADHD
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 13-17 years of age, inclusive, at the time of consent.
  • Subject must weigh more than 79.5lb.
  • The parent/LAR must be available at approximately 7:00AM (±2 hours) to dispense the dose of product for the study duration.
  • Subject, who is a female, must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test and a negative urine pregnancy test and agree to comply with any applicable requirements of the protocol.
  • Subject has an ADHD-RS-IV total score ≥28.
  • Subject is able to swallow a capsule.
  • Subject does not have hypertension and has a resting sitting blood pressure less than or equal to 135/85mmHg.

Exclusion criteria

Exclusion Criteria

  • Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder.
  • Diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary.
  • Subject is considered a suicide risk, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded.
  • Subject is underweight or overweight.
  • Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition. Mild, stable asthma is not exclusionary.
  • Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
  • Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant medication.
  • Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  • Subject has any or clinically significant laboratory abnormality.
  • Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
  • Subject has a documented allergy, , or intolerance to amphetamine or to any in the product.
  • Subject has a documented allergy, hypersensitivity, or intolerance to MPH or to any excipients in the reference product.
  • Subject has failed to fully respond to an adequate course(s) (dose and duration) of MPH or amphetamine therapy.
  • Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine). Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.
  • Subject has a positive urine drug result.
  • Subject has previously participated in this study or another clinical study involving SPD489/NRP104.
  • Subject has glaucoma.
  • Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
  • Subject is female and is pregnant or lactating.
  • Subject is well controlled on his/her current ADHD medication.
  • Subject has a pre-existing severe gastrointestinal tract narrowing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
464 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine Dimesylate

    Drug: Lisdexamfetamine dimesylate

  • Active comparator
    Methylphenidate Hydrochloride

    Drug: Methylphenidate Hydrochloride

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance

    Also known as: LDX, Vyvanse, SPD489

  • Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance

    Also known as: OROS-MPH, Concerta

  • DrugPlacebo

    Daily oral dosing in the AM for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 8

    The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Higher score indicates more severe symptoms.

    Time frame: Baseline and week 8

Secondary outcomes

  1. Percentage of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 8 - Last Observation Carried Forward (LOCF)

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Week 8

  2. Change From Baseline in Systolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment

    Time frame: Baseline and up to 8 Weeks

  3. Change From Baseline in Diastolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment

    Time frame: Baseline and up to 8 weeks

  4. Change From Baseline in Pulse Rate at up to 8 Weeks - Last on Treatment Assessment

    Time frame: Baseline and up to 8 weeks

07

Results

Posted Dec 11, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboSPD489OROS-MPH
Started91184184
Completed68155157
Not completed232927
Withdrew: Adverse event3143
Withdrew: Lost to follow-up465
Withdrew: Withdrawal by subject645
Withdrew: Protocol violation044
Withdrew: Lack of efficacy814
Withdrew: Other206

Outcome measures

PrimaryChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 8

The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Higher score indicates more severe symptoms.

Time frame:
Baseline and week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 8
units on a scalePlaceboSPD489OROS-MPH
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 8-13.4 ± 1.19-25.6 ± 0.82-23.5 ± 0.80
Statistical analysis
  • SPD489 vs OROS-MPH · mixed effects model for repeated measure · p = 0.0717 · Difference in ls mean: -2.1 · 95% CI -4.3 to 0.2
  • Placebo vs SPD489 · mixed effects model for repeated measure · p = <0.0001 · Difference in ls mean: -12.2 · 95% CI -15.1 to -9.4
  • Placebo vs OROS-MPH · mixed effects model for repeated measure · p = <0.0001 · Difference in ls mean: -10.1 · 95% CI -13.0 to -7.3
SecondaryPercentage of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 8 - Last Observation Carried Forward (LOCF)

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 8 - Last Observation Carried Forward (LOCF)
percentage of participantsPlaceboSPD489OROS-MPH
Percentage of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 8 - Last Observation Carried Forward (LOCF)34.883.181.0
Statistical analysis
  • SPD489 vs OROS-MPH · Cochran-Mantel-Haenszel · p = 0.6165
  • Placebo vs SPD489 · Cochran-Mantel-Haenszel · p = <0.0001
  • Placebo vs OROS-MPH · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryChange From Baseline in Systolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment
Time frame:
Baseline and up to 8 Weeks
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment
mmHgPlaceboSPD489OROS-MPH
Change From Baseline in Systolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment-0.8 ± 8.972.4 ± 9.460.4 ± 9.90
SecondaryChange From Baseline in Diastolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment
Time frame:
Baseline and up to 8 weeks
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment
mmHgPlaceboSPD489OROS-MPH
Change From Baseline in Diastolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment-1.2 ± 8.112.8 ± 8.412.2 ± 8.64
SecondaryChange From Baseline in Pulse Rate at up to 8 Weeks - Last on Treatment Assessment
Time frame:
Baseline and up to 8 weeks
Reported as:
Mean · bpm
Change From Baseline in Pulse Rate at up to 8 Weeks - Last on Treatment Assessment
bpmPlaceboSPD489OROS-MPH
Change From Baseline in Pulse Rate at up to 8 Weeks - Last on Treatment Assessment0.3 ± 11.324.7 ± 11.826.0 ± 10.52

Adverse events

Collected over Duration of the study, for up to 8 weeks per participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/91 (0%)39/91 (42.9%)
SPD489—1/184 (0.5%)139/184 (75.5%)
OROS-MPH—1/184 (0.5%)120/184 (65.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboSPD489OROS-MPH
Suicidal ideationPsychiatric disorders0/911/1840/184
Renal cystRenal and urinary disorders0/910/1841/184
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboSPD489OROS-MPH
Decreased appetiteMetabolism and nutrition disorders7/9198/18477/184
IrritabilityGeneral disorders9/9137/18414/184
Weight decreasedInvestigations1/9137/18424/184
HeadacheNervous system disorders7/9128/18428/184
Upper respiratory tract infectionInfections and infestations8/919/1846/184
InsomniaPsychiatric disorders0/9116/18415/184
Dry mouthGastrointestinal disorders1/9115/18411/184
NauseaGastrointestinal disorders4/9114/18415/184
Initial insomniaPsychiatric disorders2/9115/18412/184
NasopharyngitisInfections and infestations1/9111/18413/184

Baseline characteristics

Safety Set: All subjects in the Randomized Set who took at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(Years)PlaceboSPD489OROS-MPHTotal
Mean14.8 ± 1.4314.7 ± 1.3814.7 ± 1.3214.7 ± 1.37
Age, Customized
Age, Customized(Participants)PlaceboSPD489OROS-MPHTotal
<=18 years91184184459
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSPD489OROS-MPHTotal
Female306262154
Male61122122305
Region of Enrollment
Region of Enrollment(Participants)PlaceboSPD489OROS-MPHTotal
UNITED STATES91184184459
08

Study locations

79 sites
  • Melmed Center
    Scottsdale, Arizona 85254, United States
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72211, United States
  • Synergy Clinical Research Center
    National City, California 91950, United States
  • Pacific Clinical Research Medical Group
    Orange, California 92868, United States
  • SDS Clinical Trials, Inc.
    Orange, California 92868, United States
  • Peninsula Research Associates, Inc.
    Rolling Hills Estates, California 90274, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • Elite Clinical Trials
    Wildomar, California 92595, United States
  • MCB Clinical Research Centers, LLC
    Colorado Springs, Colorado 80910, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34201, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32608, United States
  • Amedica Research Institute
    Hialeah, Florida 33013, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Fidelity Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Scientific Clinical Research, Inc.
    Miami, Florida 33161, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Atlanta Institute of Medicine and Research
    Atlanta, Georgia 30328, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • AMR Baber Research Group, Inc.
    Naperville, Illinois 60563, United States
  • AMR Conventions Research
    Naperville, Illinois 60563, United States
  • American Medical Research, Inc
    Oak Brook, Illinois 60523, United States
  • Advocate Hope Children's Hospital
    Oak Lawn, Illinois 60453, United States
  • Neuroscience Research Institute, Inc
    Oak Park, Illinois 60301, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • University of Kentucky
    Lexington, Kentucky 40509, United States
  • Four Rivers Clinical Research
    Paducah, Kentucky 42003, United States
  • Neuroscientific InSights
    Rockville, Maryland 20852, United States
  • Marc Hertzman MD, PC
    Rockville, Maryland 20882, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • Clinical Neurophysiology Services, PC
    Sterling Heights, Michigan 48314, United States
  • Behavioral Medical Center - Troy
    Troy, Michigan 48083, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Comprehensive Psychiatric Associates
    Gladstone, Missouri 64118, United States
  • St Charles Psychiatric Associates
    Saint Charles, Missouri 63301, United States
  • Premier Psychiatric Research Institute
    Lincoln, Nebraska 68526, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68105, United States
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • CRCNJ - Clinical Research Center of New Jersey
    Gibbsboro, New Jersey 08026, United States
  • Neurcognitive Institute
    Mount Arlington, New Jersey 07856, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Duke Child and Family Study Center
    Durham, North Carolina 27705, United States
  • Innovis Health, LLC
    Fargo, North Dakota 58103, United States
  • North Coast Clinical Trials
    Beachwood, Ohio 44122, United States
  • University of Cincinnati Dept. of Psychiatry & Behavioral
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Nisonger Center
    Columbus, Ohio 43210, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Professional Psychiatric Services
    Mason, Ohio 45040, United States
  • Family Practice of Wadsworth, Inc.
    Wadsworth, Ohio 44281, United States
  • Cyn3rgy Research
    Gresham, Oregon 97030, United States
  • Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
    Portland, Oregon 97210, United States
  • Summit Research Network (Oregon) Inc.
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc.
    Salem, Oregon 97301, United States
  • Carolina Clinical Trials, Inc.
    Charleston, South Carolina 29407, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Research Strategies of Memphis, LLC
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials
    Austin, Texas 78731, United States
  • Claghorn-Lesem Reseach Clinic, Ltd.
    Houston, Texas 77008, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77586, United States
  • Westex Clinical Investigations
    Lubbock, Texas 79423, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • University of Texas HSC at San Antonio Dept. of Psychiatry
    San Antonio, Texas 78229, United States
  • Wharton Research Center, Inc.
    Wharton, Texas 77488, United States
  • Psychiatric & Behavioral Solutions
    Salt Lake City, Utah 84105, United States
  • University of Virginia Child and Family Psychiatry Clinical
    Charlottesville, Virginia 22903, United States
  • NeuroScience, Inc.
    Herndon, Virginia 20170, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • Summit Research Network (Seattle), LLC
    Seattle, Washington 98104, United States
  • Rockwood Clinic, P.S.
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2017 Nov;31(11):999-1014. doi: 10.1007/s40263-017-0468-2. PubMed 28980198 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Jan 2014, 21 months.

Results were first posted in Dec 2014, 10 months after primary completion.

Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2012
First posted
Mar 13, 2012
StartActual
Apr 17, 2012
Primary completionActual
Jan 22, 2014
CompletionActual
Jan 22, 2014
Results first posted
Dec 11, 2014
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01552915
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Apr 17, 2012
Primary completion
Jan 22, 2014
Completion
Jan 22, 2014
Results posted
Dec 11, 2014
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion